Marieke Sturkenboom

Dr. Marieke Sturkenboom is a Hospital Pharmacist, Clinical Pharmacologist, and Toxicologist affiliated with the Faculty of Medical Sciences at the University of Groningen. She holds positions such as Member of the board of KKGT, program leader for antifungal and antituberculosis drugs, and member of several professional organizations including IATDMCT and EAPCCT. Her research focuses on optimizing tuberculosis (TB) treatment through pharmacokinetic studies, therapeutic drug monitoring, and drug resistance mechanisms. She leads clinical trials evaluating novel drug combinations and dosing strategies for drug-resistant TB. Key contributions include international quality control programs for anti-TB drug measurements and guidelines for adverse effect management during TB therapy.

Her work spans clinical pharmacology, clinical toxicology, and infectious diseases with an emphasis on translating pharmacokinetic insights into precision medicine. Collaborations with global institutions like the WHO and international clinical networks underscore her impact on global health policies. She is actively involved in advancing diagnostic methods (e.g., finger sweat testing) and exploring drug interactions in vulnerable populations such as diabetic TB patients or those undergoing stem cell transplants.

Dr. Sturkenboom's research team participates in interdisciplinary efforts through the Microbes in Health and Disease (MHD) group at UMCG. Her studies address critical gaps in TB treatment including pediatric dosing, drug exposure variability, and the development of safety thresholds for drugs like linezolid and bedaquiline. She contributes to both basic pharmacology research and clinical implementation of evidence-based practices in antimicrobial therapy.